


REMARKS

In response to the restriction requirement, Applicants provisionally elect with traverse the invention set forth in Group II, drawn to compounds, compositions, and method of use of the compounds of formula I where A-B is $\text{NR}^5\text{-SO}_2$ and p is 2.

Regarding the election of species, please tentatively elect the compound of example 19:


N-[*(1S,2R)*-3-(Cyclopropylamino)-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-1-methyl-3,4-dihydro-1*H*-[1,2,5]thiadiazepino[3,4,5-*hi*]indole-9-carboxamide 2,2-dioxide



This compound is encompassed by claims 9-17 and 19-21.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 25 July 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988